Technical Data
Vascular Endothelial Growth Factor 111, Recombinant, Human (Vascular Endothelial Growth Factor A, VEGFA, VEGF-A, VEG, Vascular Permeability Factor, VPF)
Growth Factors, Cytokines Storage: -20CShipping: RT
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (1-3). It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cystine knot structure (4). Humans normally express alternately spliced isoforms of 121, 145, 165, 183, 189, and 206aa in length (4). VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189 (3, 4). Additionally, an active ~18kD form, VEGF111, can be induced in tumor cells by treatment with genotoxic agents and ultraviolet (UV-B) irradiation (5). Like VEGF121, VEGF111 lacks the basic heparin-binding region encoded by exons 6 and 7, and is freely diffusible (4, 5). VEGF111 also lacks major proteolytic cleavage sites encoded by exon 5, giving it additional stability. Human VEGF111 shares 87% aa sequence identity with corresponding regions of mouse and rat VEGF, 93% with feline, equine and bovine VEGF, and 91%, 95% and 96% with ovine, canine and porcine VEGF, respectively. All VEGF forms bind the single pass receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells (4). Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity (3, 4). VEGF is required during embryogenesis to regulate the proliferation, migration, and survival of endothelial cells (3, 4). In adults, VEGF functions mainly in wound healing and in female during reproductive cycle (3). Pathologically, it is involved in tumor angiogenesis and vascular leakage (6, 7).

Synthetic peptide corresponding to human VEGF111 (Ala27-Arg137; ABB58912) expressed in E. coli.

MW: The methionyl form~13kD and a truncated form~12.8kD
The recombinant human VEGF 111 migrates as an ~12-13kD protein in
SDS-PAGE under reducing conditions.

Activity: Measured by its ability to stimulate proliferation of HUVE cells (Conn, G. et al., 1990, Proc. Natl. Acad. Sci. USA 87:1323-1327).
The ED50 for this effect is typically 0.6-3ng/ml.. The cell number is assessed in a fluorometric
assay using the redox sensitive dye, Resazurin.

Storage and Stability:
12 months from date of receipt, 20 to 70C as supplied.
1 month, 2 to 8C under sterile conditions after reconstitution.
3 months, 20 to 70C under sterile conditions after reconstitution.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Source: Recombinant human VEGF, E. coli
Purity: Purified 95%, as determined by SDS-PAGE under reducing conditions and visualized by silver stain. Endotoxin: 1.0 EU/1ug (LAL).
Concentration: As reported
Form: Supplied as a lyophilized powder from a sterile filtered solution in 30% CH3CN and 0.1% TFA.
Reconstitute with sterile PBS to 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Leung, D.W. et al., 1989, Science 246:1306. 2. Keck, P.J. et al., 1989, Science 246:1309. 3. Byrne, A.M. et al., 2005, J. Cell. Mol. Med. 9:777. 4. Robinson, C.J. and Stringer, S.E., 2001, J. Cell. Sci. 114:853.
5. Mineur, P. et al., 2007, J. Cell Biol. 179:1261. 6. Weis, S.M. & D.A. Cheresh, 2005, Nature 437:497. 7. Thurston, G., 2002, J. Anat. 200:575.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.